A detailed history of Bank Julius Baer & Co. Ltd, Zurich transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bank Julius Baer & Co. Ltd, Zurich holds 13,503 shares of VRTX stock, worth $6.78 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
13,503
Previous 286,108 95.28%
Holding current value
$6.78 Million
Previous $120 Million 94.71%
% of portfolio
0.03%
Previous 0.46%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $107 Million - $132 Million
-272,605 Reduced 95.28%
13,503 $6.33 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $33.6 Million - $36.8 Million
82,476 Added 40.5%
286,108 $120 Million
Q4 2023

May 16, 2024

BUY
$343.0 - $410.68 $45.2 Million - $54.2 Million
131,891 Added 183.84%
203,632 $82.9 Million
Q4 2023

May 16, 2024

SELL
$343.0 - $410.68 $73.5 Million - $88 Million
-214,367 Reduced 74.93%
71,741 $29.2 Million
Q4 2023

Feb 02, 2024

BUY
$343.0 - $410.68 $6.17 Million - $7.39 Million
18,002 Added 9.7%
203,632 $82.9 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $4.72 Million - $5.06 Million
13,969 Added 8.14%
185,630 $64.6 Million
Q2 2023

Jul 24, 2023

BUY
$314.42 - $351.91 $54 Million - $60.4 Million
171,661 New
171,661 $60.4 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $307,871 - $351,209
1,087 Added 0.64%
171,457 $54 Million
Q4 2022

Jan 24, 2023

BUY
$285.76 - $321.48 $46.4 Million - $52.2 Million
162,295 Added 2009.85%
170,370 $49.2 Million
Q3 2022

Nov 04, 2022

BUY
$273.83 - $305.53 $1.03 Million - $1.15 Million
3,767 Added 87.44%
8,075 $2.34 Million
Q2 2022

Jul 22, 2022

BUY
$234.96 - $292.55 $279,367 - $347,841
1,189 Added 38.12%
4,308 $1.21 Million
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $588,755 - $693,919
2,659 Added 578.04%
3,119 $814,000
Q4 2021

Feb 15, 2022

SELL
$177.01 - $223.45 $799,200 - $1.01 Million
-4,515 Reduced 90.75%
460 $101,000
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $379,649 - $424,858
2,093 Added 72.62%
4,975 $902,000
Q2 2021

Jul 23, 2021

BUY
$187.49 - $221.1 $131,805 - $155,433
703 Added 32.26%
2,882 $581,000
Q1 2021

May 10, 2021

SELL
$207.02 - $241.31 $2.91 Million - $3.39 Million
-14,069 Reduced 86.59%
2,179 $468,000
Q4 2020

Feb 24, 2021

SELL
$207.01 - $276.09 $357,713 - $477,083
-1,728 Reduced 9.61%
16,248 $3.84 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $1.98 Million - $2.64 Million
9,580 Added 114.1%
17,976 $3.84 Million
Q3 2020

Nov 10, 2020

BUY
$255.65 - $303.1 $567,543 - $672,882
2,220 Added 35.95%
8,396 $2.23 Million
Q2 2020

Aug 12, 2020

SELL
$225.48 - $295.8 $191,883 - $251,725
-851 Reduced 12.11%
6,176 $1.79 Million
Q1 2020

May 13, 2020

BUY
$199.77 - $247.81 $1.4 Million - $1.74 Million
7,027 New
7,027 $1.67 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Bank Julius Baer & Co. Ltd, Zurich Portfolio

Follow Bank Julius Baer & Co. Ltd, Zurich and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

News

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.